share_log

Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Tang Capital Partners, LP(0.0%),Tang Capital Management, LLC(0.0%), etc.

SEC announcement ·  Feb 14 16:04
Summary by Moomoo AI
TransCode Therapeutics, Inc., a biopharmaceutical company, was the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC), dated December 31, 2023. The amendment was filed by Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang, the manager of Tang Capital Management. The filing indicates that these entities and individual collectively own 0 shares of TransCode Therapeutics' common stock and consequently represent 0.0% of the class. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is typically used by persons who have acquired beneficial ownership of more than 5% of a class of equity securities. The filing also includes a certification by Kevin Tang, stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The principal business office address for the reporting persons is listed as 4747 Executive Drive, Suite 210, San Diego, CA 92121.
TransCode Therapeutics, Inc., a biopharmaceutical company, was the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC), dated December 31, 2023. The amendment was filed by Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang, the manager of Tang Capital Management. The filing indicates that these entities and individual collectively own 0 shares of TransCode Therapeutics' common stock and consequently represent 0.0% of the class. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is typically used by persons who have acquired beneficial ownership of more than 5% of a class of equity securities. The filing also includes a certification by Kevin Tang, stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The principal business office address for the reporting persons is listed as 4747 Executive Drive, Suite 210, San Diego, CA 92121.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more